Related Experiment Video

Updated: May 9, 2026

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

The protein p17 signaling pathways in cancer

Klaus Heese1

  • 1Graduate School of Biomedical Science and Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 133-791, Republic of Korea, klaus@hanyang.ac.kr.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|August 1, 2013
PubMed

Insights

The novel neuronal protein P17, crucial in tumorigenesis, interacts with specific proteins and drives cell cycle progression. Targeting P17 offers a new strategy for cancer treatment, potentially influencing tumor suppressor p53 pathways.

Area of Science:

  • Molecular biology
  • Cell biology
  • Biocomputational analysis

Background:

  • P17 is a novel neuronal protein.
  • It is expressed at low levels in non-neuronal tissues under physiological conditions.
  • P17 is implicated in tumorigenic effects.

Purpose of the Study:

  • To elucidate the mode of action of P17.
  • To identify P17 interacting proteins.
  • To explore P17's role in cell cycle regulation and its potential as a therapeutic target.

Main Methods:

  • Molecular biology techniques
  • Cellular assays
  • Biocomputational analysis

Main Results:

  • P17 associates with mitochondria.
  • P17 interacts with proteins TMEM115, YPEL3, ERP44, CDK5RAP, and NNAT.
  • P17 induces G0/G1 cell cycle arrest and promotes survival of proliferating cells.

Conclusions:

  • P17 plays a significant role in cell cycle progression and cell survival.
  • Interference with P17 activity presents a novel therapeutic strategy for cancer.
  • Targeting P17 may influence tumor suppressor p53 signaling pathways for cancer treatment.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...